Rice Bran-based Supplemental Foods for the Treatment of Childhood Malnutrition

Severe Acute Malnutrition Clinical Trial

Official title:

Rice Bran in Ready-to-use Therapeutic Foods for Microbiota-targeted Treatment of Childhood Malnutrition

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05319717
• Other study ID #: CSU IRB#:1823
• Status: Completed
• Phase: Phase 2
• Start date: December 1, 2022
• Est. completion date: August 31, 2023

Study information

• Verified date: June 2024
• Source: Colorado State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy of treating children with severe acute malnutrition (SAM) with a locally produced ready-to-use therapeutic food (RUTF) with or without rice bran.

Description:

Rice bran is a nutrient dense food ingredient with prebiotics and phytochemicals, as well as vitamins, fatty acids, and amino acids. The investigators will determine if the inclusion of rice bran to locally produced RUTFs will improve SAM treatment for children in Indonesia. This will be assessed by standard anthropometric measures and determining the modulation of the malnourished child's gut microbiome and metabolome. The study will also assess rates of relapse in the entire cohort.

This study will yield new information of direct importance and impact to public health nutrition and advance our knowledge and treatment of SAM in Indonesia. Investigation of the gut-microbiota metabolism following consumption of rice bran provided in RUTFs compared to RUTF without rice bran included will provide key mechanistic insights for repairing nutrient absorptive functions in the gut, sustaining gut health in treated children and inform long-term treatment solutions for SAM.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: August 31, 2023
• Est. primary completion date: August 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 59 Months

Eligibility

Inclusion Criteria:

• Willing to participate in the study, with parent(s) signing the informed consent. If the caretaker denies the participation of the child, the child will be enrolled for treatment through the health system, but the information will be not considered for the purpose of the trial.

• Child identified with a weight-for-height z-score WHZ of < -2.5 (SAM children and children with advanced moderate acute malnutrition) and/or mid-upper arm circumference (MUAC) <115 mm) or a child with mild to moderate nutritional edema (regardless of anthropometry).

• Being qualified for outpatient treatment.

• Aged 6-59 months old upon enrolment

• Pass appetite test (taste test) (as stipulated by WHO guidelines on the treatment of SAM). See appetite test document attached.

• Not having consumed RUTF in the last two months

Exclusion Criteria:

• Children detected with severe acute malnutrition younger than 6 months of age will be excluded from the project, as well as any child with a body weight <4.0 kg.

• Children 6-59 months old who, when diagnosed with SAM, have been detected with medical complications, with TB, HIV positive status, one or more signs from the Integrated Management of Childhood Illness (IMCI) guidelines, severe oedema (+++) or who have failed the appetite test (see appetite test document attached).

• Medical complications include: Cough/difficulty in breathing; Diarrhea; Fever; Ear Problems. IMCI signs will be identified according to WHO definition and include not able to drink or breastfeed; vomiting; convulsions; lethargy.

• Participating in another clinical trial

• Any congenital disorder that interferes with normal nutrient intake; chronic conditions including but not exclusively disorders of heart, kidney or liver (children to be screened by a physician).

• SAM with complications requiring hospital treatment. (Upon discharge from hospital, the child will be re-evaluated for inclusion in the study).

• Siblings will not be allowed to participate in the trial

Withdrawal criteria:

• Not consuming the RUTF supplementation at all in >4 days a week in 2 consecutive weeks.

• Not providing samples or completing forms/questionnaires at study visits

• Developing medical complications requiring hospitalization

• Not gaining weight after 1 month of treatment

• Major reactions to intervention

Related Conditions & MeSH terms

• Malnutrition
• Severe Acute Malnutrition

Intervention

Dietary Supplement:
• Ready-to-use therapeutic food with heat stabilized rice bran
Children assigned to the experimental group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food that contains 5% heat stabilized rice bran.
• Ready-to-use therapeutic food (no rice bran)
Children assigned to the active comparator group will be treated for severe acute malnutrition with a novel ready-to-use therapeutic food (no rice bran).

Locations

Country	Name	City	State
Indonesia	Savica	Jember	East Java

Sponsors (4)

Lead Sponsor	Collaborator
Colorado State University	Institute of Research for Development, France, Savica, Indonesia, Thrasher Research Fund

Country where clinical trial is conducted

Indonesia, 

References & Publications (1)

Weber AM, Barbazza S, Fauzi MD, Rachmadewi A, Zuhrina R, Putri FK, Campos Ponce M, Hoeven MV, Rimbawan R, Nasution Z, Giriwono PE, Wieringa FT, Soekarjo DD, Ryan EP. Solutions to Enhance Health with Alternative Treatments (SEHAT) protocol: a double-blinded randomised controlled trial for gut microbiota-targeted treatment of severe acute malnutrition using rice bran in ready-to-use therapeutic foods in Indonesia. BMJ Open. 2023 Nov 24;13(11):e076805. doi: 10.1136/bmjopen-2023-076805. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the locally produced ready-to-use therapeutic food + heat stabilized rice bran as compared to locally produced ready-to-use therapeutic food alone in the treatment of severe acute malnutrition as determined by child weight.	This will be assessed by measures of: - Weight	Baseline, week 4, week 8, and week 16
Primary	Efficacy of the locally produced ready-to-use therapeutic food + heat stabilized rice bran as compared to locally produced ready-to-use therapeutic food alone in the treatment of severe acute malnutrition as determined by mid-upper arm circumference.	This will be assessed by measures of: -Mid-upper arm circumference	Changes between baseline, week 4, week 8, and week 16
Primary	Efficacy of the locally produced ready-to-use therapeutic food + heat stabilized rice bran as compared to locally produced ready-to-use therapeutic food alone in the treatment of severe acute malnutrition as determined by morbidity.	This will be assessed by measures of: - Morbidity (diarrhea, fever, vomiting, upper or lower respiratory infection)	Changes between baseline, week 4, week 8, and week 16
Secondary	Stool microbiota composition	Determine stool microbiota composition of infants in both arms over time using 16S rRNA sequencing and shotgun metagenomic sequencing.	Changes between baseline, week 4, week 8, and week 16
Secondary	Dried blood spot metabolite profile	Dried blood spots will be analyzed for metabolites.	Changes between baseline, week 4, week 8, and week 16
Secondary	Relapse	Determine the number of participants that experience severe acute malnutrition relapse 4 weeks after the treatment/intervention has ended.	Week 16 (end of study)
Secondary	Percent of children recovered	The number of children recovered in the 4 week treatment period will be determined as well as the time to recovery (days).	Baseline, week 4, week 8, and week 16